PLEASANTON, Calif.--(BUSINESS WIRE)-- IntegenX Inc., a privately held company that is a leader in the emerging field of rapid human DNA identification, today announced that it has acquired SV Corp, a wholly owned subsidiary of GE Healthcare Bio-Sciences. IntegenX will leverage SV Corp’s products and intellectual property assets to expand its consumables offering and to accelerate the commercialization of its RapidHIT™ 200 Human DNA Identification System. GE Healthcare Bio-Sciences is a subsidiary of GE Healthcare. Financial terms of the agreement were not disclosed.
“This acquisition marks an important milestone in IntegenX’s introduction of our first commercially available system for rapid human DNA identification,” said Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX. “The SV Corp acquisition brings to IntegenX proprietary products and a proven and protected IP estate containing key technical know-how in capillary electrophoresis, separation, sample preparation, and separation matrix.”
As a result of the acquisition, IntegenX will take over supplying capillaries and matrix to the more than 100 existing users of GE’s MegaBACE™ sequencers. These products will also be integrated into the RapidHIT system.
Set to commercially launch later this year, the IntegenX RapidHIT 200 is a self-contained Human Identification (HID) system that automates and accelerates the process of producing standardized DNA profiles from mouth swabs and other human samples in less than 90 minutes. Numerous local, state, national, and international law enforcement and security agencies use DNA-based human identification to make informed identification decisions regarding the arrest, detention, or release of suspects, as well as to analyze crime scene evidence. The RapidHIT system will allow rapid DNA analysis at the point of collection — such as on arrest or detention — a new approach in the usage of DNA profiles as an actionable biometric similar to fingerprints.
For more information please visit www.IntegenX.com.
About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, Next-Gen Sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented DNA and RNA reagents including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.
IntegenX and RapidHIT are trademarks of IntegenX Inc. MegaBACE is a trademark of GE Healthcare. All other brands may be trademarks of their respective holders.
Contact:
for IntegenX
Nicole Litchfield, 415-793-6468
nicole@bioscribe.com
